Review highlights model gap in neutrophilic asthma research

A new review in Molecular Medicine argues that progress in neutrophilic asthma has been slowed not just by the disease’s complexity, but by the limits of the models used to study it. The paper, by Jialin Yao, Jingjing Lu, and Jing Gao, synthesizes current in vivo and in vitro approaches used to study this severe, steroid-insensitive asthma endotype, with a focus on how well they reproduce core features such as airway neutrophilia, persistent inflammation, and poor glucocorticoid response. Broader literature supports the need for that reset: neutrophilic asthma is generally considered a type 2-low phenotype, is linked with worse control and higher exacerbation burden, and still lacks consistently effective targeted therapies. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the review is a reminder that translational respiratory research depends on model quality. Better experimental systems could sharpen understanding of steroid-resistant airway inflammation, Th17- and inflammasome-linked pathways, and candidate targets such as IL-17, NLRP3, NET-related mechanisms, and other non-type 2 drivers. That matters not only for human drug development, but also for comparative and naturally occurring animal airway disease research, where model selection can shape how confidently findings move toward clinical use. (pubmed.ncbi.nlm.nih.gov)

What to watch: Expect attention to shift toward models with stronger mechanistic fidelity, especially those that better capture corticosteroid resistance and heterogeneous, real-world neutrophilic airway disease. (pubmed.ncbi.nlm.nih.gov)